A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany
- 1 September 2006
- journal article
- Published by Springer Science and Business Media LLC in The European Journal of Health Economics
- Vol. 7 (3), 165-172
- https://doi.org/10.1007/s10198-006-0347-0
Abstract
Decision support techniques, Atypical antipsychotics, Schizophrenia, Health care costs,Keywords
This publication has 16 references indexed in Scilit:
- Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic studyProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
- Kostenanalyse der Schizophrenie-Behandlung in Deutschland - Vergleich von Olanzapin, Risperidon und Haloperidol mit Hilfe eines klinischen Entscheidungsmodells -Gesundheitsökonomie & Qualitätsmanagement, 2001
- Die Kosten der Schizophrenie - was wissen wir (nicht)?Psychiatrische Praxis, 2001
- Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modelingJournal of Medical Economics, 2001
- Cost Analysis of the Treatment of Schizophrenia in the UKPharmacoEconomics, 2000
- Atypical antipsychotics: are some more atypical than others?Psychopharmacology, 2000
- Costs of schizophreniaThe British Journal of Psychiatry, 1997
- Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapineAmerican Journal of Psychiatry, 1997
- Dr. Meltzer and Mr. Cola ReplyAmerican Journal of Psychiatry, 1995
- The Cost of Suicide and Suicide Attempts in the United StatesClinical Neuropharmacology, 1995